Dividend Power Score
A single, comprehensive score designed to measure the true strength of a company’s dividend.
This score combines three essential pillars of dividend quality:
Consistency – Measures how reliable the dividend has been over time, focusing on payment history, stability, and the absence of cuts or suspensions.
Payability – Assesses the company’s financial ability to sustain its dividend, taking into account cash flow, earnings coverage, balance sheet strength, and overall financial health.
Growth – Evaluates the long-term growth of both the dividend and the company’s share price, highlighting businesses that consistently increase payouts while creating shareholder value.
Higher scores identify companies that have historically delivered dependable income alongside sustained dividend growth and long-term capital appreciation.
Company Overview
Alterity Therapeutics Limited is a clinical-stage biotechnology company focused on the discovery and development of disease-modifying therapies for neurodegenerative disorders. The company operates within the biotechnology and pharmaceutical research industries, with a primary emphasis on conditions associated with abnormal protein aggregation and iron dysregulation in the brain. Its core strategic focus is on developing small-molecule compounds that target underlying disease mechanisms rather than symptomatic relief.
The company’s principal asset is ATH434, a proprietary oral small-molecule drug candidate designed to modulate iron accumulation and inhibit toxic protein aggregation in neurodegenerative diseases. Alterity’s primary target indications include Multiple System Atrophy (MSA) and Parkinson’s disease. The company traces its origins to Prana Biotechnology Limited, which was founded in 1997 and later rebranded as Alterity Therapeutics Limited in 2019 to reflect its narrowed focus on late-stage neurodegenerative disease programs.
Business Operations
Alterity Therapeutics operates primarily as a research and development organization, generating value through the advancement of its clinical pipeline rather than commercial product sales. Its operations are centered on preclinical research, clinical trials, regulatory engagement, and intellectual property management. The company does not currently generate material operating revenue and relies on equity financing, grants, and partnerships to fund its activities.
The company’s lead program, ATH434, is being evaluated in clinical trials for Multiple System Atrophy, a rare and fatal neurodegenerative disease with no approved disease-modifying treatments. Alterity conducts its clinical development activities through a combination of internal management and external contract research organizations, with trials conducted across multiple international sites. The company holds global rights to its technology platform and drug candidates.
Strategic Position & Investments
Alterity’s strategic direction centers on establishing ATH434 as a first-in-class disease-modifying therapy for MSA, with potential expansion into other synucleinopathies, including Parkinson’s disease. The company’s investment strategy prioritizes advancing its lead asset through clinical development milestones while maintaining a streamlined pipeline focused on iron biology and neurodegeneration.
The company has historically invested in expanding its intellectual property portfolio surrounding metal-protein interaction modulation. Alterity does not currently report ownership of revenue-generating subsidiaries or a diversified portfolio of unrelated investments, instead maintaining a concentrated strategy focused on its core therapeutic platform. Any future strategic partnerships or licensing arrangements are expected to support late-stage development and potential commercialization.
Geographic Footprint
Alterity Therapeutics is headquartered in Australia, with its corporate domicile in Melbourne, Victoria. Despite its Australian base, the company maintains a significant operational and investor presence in the United States, where it is listed on the NASDAQ Capital Market and conducts a substantial portion of its clinical and regulatory activities.
The company’s clinical trials and research collaborations extend across North America, Europe, and Australia, reflecting its global approach to drug development for rare neurological diseases. This international footprint allows Alterity to access specialized clinical sites, regulatory expertise, and patient populations necessary for advanced-stage neurodegenerative disease research.
Leadership & Governance
Alterity Therapeutics is led by an executive team with experience in biotechnology, pharmaceuticals, and capital markets, with governance oversight provided by an independent board of directors. The leadership emphasizes disciplined capital allocation, scientific rigor, and a focused development strategy aimed at addressing high unmet medical needs.
Key executives include:
- David Stamler – President and Chief Executive Officer
- Stephen D. Wicks – Non-Executive Chairman
- Andrew Gunn – Chief Financial Officer
- David R. Finkelstein – Chief Scientific Officer
- Nicole Williams – Company Secretary and General Counsel
The leadership team’s strategic vision centers on advancing disease-modifying therapies through efficient clinical execution while positioning the company for potential regulatory approval and strategic partnerships.